Prieur Marc sold $284K of ATR

Prieur Marc (Segment President) sold 2,000 shares of APTARGROUP, INC. (ATR) at $141.99 ($0.28M total) on 2026-11-02.

Original reporting
SEC EDGAR · Prieur Marc
Published Nov 3, 2026, 9:22 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 9:25 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ATR
Bearish
medium confidence
Mentioned
$ATR
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ATRBearishLow
01

Why it matters

A modest insider sell by a senior executive may cause short‑term price softness but is unlikely to drive significant moves.

02

Market read

The filing provides new, albeit small, insider sell data that could be factored into short‑term trading decisions.

03

What to watch

Potential upcoming corporate actions or earnings that may have prompted the sale.

Relevance 4/10Novelty 4/10Timing: post‑market today

Background

SEC Form 4 filings disclose insider transactions and are primary sources for such events.

Company-level read

Ticker impact

$ATRBearishMedium confidence
Context

Segment President Marc Prieur sold 2,000 shares of APTARGROUP for $283,974, reducing his stake to 13,823 shares.

Expected impact

likely pressure as the market prices in the insider sell

Evidence & confidence

A $284K sale by a senior officer is a material insider transaction, but the amount is small relative to the company's market cap, so impact is limited.

Market effects

Minimal; the sale does not affect the broader sector.

None; the transaction is company‑specific.

Low; no broader market relevance.

Counterpoint

The sale could be routine portfolio rebalancing and not indicative of negative outlook.

Key entities

  • APTARGROUP, INC.

    US‑listed provider of technology services, ticker ATR.

  • Marc Prieur

    Segment President and officer of APTARGROUP.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ATRHighAI 8/10

Aptar Q3 2026 slides: broad growth, strong Pharma pipeline

AptarGroup (NYSE:ATR) reported Q3 2026 sales of $1.019B, up 6% YoY, with adjusted EPS of $1.52 beating estimates. Growth was seen across all segments, but margins were pressured. The Pharma segment grew 2% reported, 1% core, while Beauty grew 9% reported, 8% core, and Closures grew 11%. Management expects Q4 adjusted EPS of $1.39-$1.47, up 17% YoY.

$ATRMed

AptarGroup Inc (ATR) (Q3 2026) Earnings Call Highlights: Core Sales Grow 5% as Pharma

AptarGroup Inc (ATR) reported Q3 2026 core sales growth of 5% across all segments, with Pharma, Beauty, and Closures up 8%, 8%, and 11% respectively. Adjusted EPS was $1.52, down 6% YoY. Pharma growth was impacted by emergency medicine destocking, expected to affect full-year sales by $65M. Beauty and Closures margins declined due to operational challenges. CEO Gael Touya outlined plans for multi-year transformation in Beauty and reiterated long-term growth targets for Pharma.

$ATRMedAI 8/10

What AptarGroup (ATR) Said on Its Q3 Earnings Call

AptarGroup (ATR) reported Q3 earnings, highlighting growth in beauty, closures, and pharma sectors. Beauty core sales rose 8%, while closures saw 11% growth. Pharma developments include collaborations and acquisitions. The company recorded a $61.2M charge related to its Russian subsidiary. ATR forecasted Q4 adjusted EPS of $1.39-$1.47, up 17% YoY. Full-year capex is expected at $260M-$280M. Virginie Maes will lead Aptar Pharma starting January 1.